榮盛石化(002493.SZ):2020年1-2月累計新增借款95.9億元
格隆匯3月12日丨榮盛石化(002493.SZ)公佈,截至2019年12月31日,公司經未經審計淨資產416.52億元,借款餘額958.78億元。截至2020年2月29日(未經審計),公司借款餘額1054.68億元,較2019年末累計新增借款95.90億元、佔2019年未經審計淨資產的23.02%。
公司的新增借款主要系浙石化煉化一體化項目建設及生產經營所需補充的流動資金,隨着浙石化煉化一體化項目一期的順利投產,公司的綜合競爭能力將得到進一步提升。公司新增借款屬於公司正常經營活動,對公司生產經營和償債能力無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.